Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells

Microvascular Research

Volumn 97, Issue , 2015, Pages 55-64

  Mochin, Maria T ^a   Underwood, Karen F ^a   Cooper, Brandon ^a   McLenithan, John C ^a   Pierce, Adam D ^a   Nalvarte, Cesar ^a   Arbiser, Jack ^b,c   Karlsson, Anna I ^b,c   Moise, Alexander R ^d   Moskovitz, Jackob ^d   Passaniti, Antonino ^a,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e Veterans Administration Rehabilitation Research and Development Service   (United States)

Author keywords

Angiogenesis; Antioxidant enzymes; Endothelial cell differentiation; Oxidative stress; Transcriptional factors

Indexed keywords

ALDEHYDE REDUCTASE; CYSTEINE; GLUTATHIONE REDUCTASE; METHIONINE; METHIONINE SULFOXIDE REDUCTASE A; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; ANGIOGENESIS INHIBITOR; ANTIOXIDANT; DNA; GLUCOSE; METHIONINE SULFOXIDE REDUCTASE; OXIDIZING AGENT; RUNX1 PROTEIN, HUMAN; RUNX2 PROTEIN, HUMAN;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DIFFERENTIATION; COMPLEX FORMATION; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; WESTERN BLOTTING; BINDING SITE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; ENZYME SPECIFICITY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TIME FACTOR; UMBILICAL VEIN ENDOTHELIAL CELL;

ALDEHYDE REDUCTASE; ANGIOGENESIS INHIBITORS; ANTIOXIDANTS; BINDING SITES; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERGLYCEMIA; METHIONINE SULFOXIDE REDUCTASES; NEOVASCULARIZATION, PATHOLOGIC; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHENOTYPE; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 84918500125     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2014.09.008     Document Type: Article

References (69)

1. Agbas A., Moskovitz J. The role of methionine oxidation/reduction in the regulation of immune response. Curr. Signal Transduct. Ther. 2009, 4:46-50.
2. Akamatsu Y., et al. A simple screening for mutant DNA binding proteins: application to murine transcription factor PEBP2alpha subunit, a founding member of the Runt domain protein family. Gene 1997, 185:111-117.
3. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv. Cardiol. 2008, 45:1-16.
4. Blyth K., et al. The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 2005, 5:376-387.
5. Brash D.E., Havre P.A. New careers for antioxidants. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13969-13971.
6. Brautigam L., et al. Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20057-20062.
7. Bronckers A.L., et al. Expression of Runx2/Cbfa1/Pebp2alphaA during angiogenesis in postnatal rodent and fetal human orofacial tissues. J. Bone Miner. Res. 2005, 20:428-437.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
9. Cao Y. Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity. Cell Metab. 2013, 18:478-489.
10. Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat. Rev. Endocrinol. 2014, 10:530-539.
11. Cao Y., Langer R. Optimizing the delivery of cancer drugs that block angiogenesis. Sci. Transl. Med. 2010, 2:15ps3.
12. Cao Y., et al. Forty-year journey of angiogenesis translational research. Sci. Transl. Med. 2011, 3:114rv3.
13. Counter C.M., et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16:1217-1222.
14. De Luca A., et al. Methionine sulfoxide reductase A down-regulation in human breast cancer cells results in a more aggressive phenotype. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18628-18633.
15. D'Souza D.R., et al. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. J. Biol. Chem. 2009, 284:17947-17955.
16. Fomenko D.E., et al. MsrB1 (methionine-R-sulfoxide reductase 1) knock-out mice: roles of MsrB1 in redox regulation and identification of a novel selenoprotein form. J. Biol. Chem. 2009, 284:5986-5993.
17. Fowlkes J.L., et al. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 2008, 149:1697-1704.
18. Gius D. Redox-sensitive signaling factors and antioxidants: how tumor cells respond to ionizing radiation. J. Nutr. 2004, 134:3213S-3214S.
19. Glotzer D.J., et al. Impaired skin and hair follicle development in Runx2 deficient mice. Dev. Biol. 2008, 315:459-473.
20. Hamanaka R.B., Chandel N.S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem. Sci. 2010, 35:505-513.
21. Hanson S., et al. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. Oncogene 2005, 24:1641-1647.
22. Jones D.P. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol. 2008, 295:C849-C868.
23. Juttner K.V., Perry M.J. High-dose estrogen-induced osteogenesis is decreased in aged RUNX2(+/-) mice. Bone 2007, 41:25-32.
24. Kim J.A., et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
25. Kohen R., Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 2002, 30:620-650.
26. Komori T., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts [see comments]. Cell 1997, 89:755-764.
27. Kurokawa M., et al. A conserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts. J. Biol. Chem. 1996, 271:16870-16876.
28. Lass A., et al. Caloric restriction prevents age-associated accrual of oxidative damage to mouse skeletal muscle mitochondria. Free Radic. Biol. Med. 1998, 25:1089-1097.
29. Lei K.F., et al. Identification of MSRA gene on chromosome 8p as a candidate metastasis suppressor for human hepatitis B virus-positive hepatocellular carcinoma. BMC Cancer 2007, 7:172.
30. Leto T.L., Geiszt M. Role of Nox family NADPH oxidases in host defense. Antioxid. Redox Signal. 2006, 8:1549-1561.
31. Lu H., et al. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 2003, 144:346-352.
32. Miki H., Funato Y. Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species. J. Biochem. 2012, 151:255-261.
33. Moskovitz J. Methionine sulfoxide reductases: ubiquitous enzymes involved in antioxidant defense, protein regulation, and prevention of aging-associated diseases. Biochim. Biophys. Acta 2005, 1703:213-219.
34. Moskovitz J., et al. Escherichia coli peptide methionine sulfoxide reductase gene: regulation of expression and role in protecting against oxidative damage. J. Bacteriol. 1995, 177:502-507.
35. Moskovitz J., et al. Identification and characterization of a putative active site for peptide methionine sulfoxide reductase (MsrA) and its substrate stereospecificity. J. Biol. Chem. 2000, 275:14167-14172.
36. Moskovitz J., et al. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12920-12925.
37. Moskovitz J., et al. Purification and characterization of methionine sulfoxide reductases from mouse and Staphylococcus aureus and their substrate stereospecificity. Biochem. Biophys. Res. Commun. 2002, 290:62-65.
38. Namba K., et al. Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MSS31. Oncogene 2000, 19:106-114.
39. Nomura T., et al. Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure. Biopolymers 2009, 91:78-84.
40. Oien D.B., Moskovitz J. Substrates of the methionine sulfoxide reductase system and their physiological relevance. Curr. Top. Dev. Biol. 2008, 80:93-133.
41. Oien D.B., et al. MsrA knockout mouse exhibits abnormal behavior and brain dopamine levels. Free Radic. Biol. Med. 2008, 45:193-200.
42. Oien D.B., et al. Detection of oxidized methionine in selected proteins, cellular extracts and blood serums by novel anti-methionine sulfoxide antibodies. Arch. Biochem. Biophys. 2009, 485:35-40.
43. Oien D.B., et al. Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells. J. Mol. Neurosci. 2009, 39:323-332.
44. Oien D.B., et al. Caloric restriction alleviates abnormal locomotor activity and dopamine levels in the brain of the methionine sulfoxide reductase A knockout mouse. Neurosci. Lett. 2010, 468:38-41.
45. Ortiz A.N., et al. Quantification of reserve pool dopamine in methionine sulfoxide reductase A null mice. Neuroscience 2011, 177:223-229.
46. Pierce A.D., et al. Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype. J. Cell. Biochem. 2012, 113:218-292.
47. Pili R., et al. Altered angiogenesis underlying age-dependent changes in tumor growth. J. Natl. Cancer Inst. 1994, 86:1303-1314.
48. Potente M., et al. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
49. Qiao M., et al. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a PI3K/ERK-dependent and Akt-independent signaling pathway. J. Biol. Chem. 2004, 279:42709-42718.
50. Qiao M., et al. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J. Biol. Chem. 2006, 281:7118-7128.
51. Qutub A.A., Popel A.S. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol. Cell. Biol. 2008, 28:5106-5119.
52. Renard P., et al. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 2001, 29:E21.
53. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int. J. Clin. Oncol. 2003, 8:200-206.
54. Sohal R.S., Orr W.C. Role of oxidative stress in senescence. Aging (Milano) 1998, 10:149-151.
55. Srivastava S.K., et al. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 2005, 26:380-392.
56. Stadtman E.R., et al. Oxidation of methionine residues of proteins: biological consequences. Antioxid. Redox Signal. 2003, 5:577-582.
57. Stadtman E.R., et al. Methionine oxidation and aging. Biochim. Biophys. Acta 2005, 1703:135-140.
58. Sun L., et al. Runt-related gene 2 in endothelial cells: inducible expression and specific regulation of cell migration and invasion. Cancer Res. 2001, 61:4994-5001.
59. Sun L., et al. Regulation of TGFß1-mediated growth inhibition and apoptosis by RUNX2 isoforms. Oncogene 2004, 23:4722-4734.
60. Sundaresan M., et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem. J. 1996, 318(Pt 2):379-382.
61. Tahirov T.H., et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 2001, 104:755-767.
62. Tsuji K., et al. Aged mice require full transcription factor, Runx2/Cbfa1, gene dosage for cancellous bone regeneration after bone marrow ablation. J. Bone Miner. Res. 2004, 19:1481-1489.
63. Underwood K.F., et al. Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by Vitamin D3 (cholecalciferol) prohormone activity. J. Bone Miner. Res. 2012, 27:913-925.
64. Underwood K.F., et al. A quantitative assay to study protein:DNA interactions, discover transcriptional regulators of gene expression, and identify novel anti-tumor agents. J. Vis. Exp. 2013, (78). (Aug 31).
65. Vitolo M.I., et al. The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol. Ther. 2007, 6:856-863.
66. Weissbach H., et al. Methionine sulfoxide reductases: history and cellular role in protecting against oxidative damage. Biochim. Biophys. Acta 2005, 1703:203-212.
67. Winterbourn C.C., Hampton M.B. Thiol chemistry and specificity in redox signaling. Free Radic. Biol. Med. 2008, 45:549-561.
68. Wood L.G., et al. Biomarkers of lipid peroxidation, airway inflammation and asthma. Eur. Respir. J. 2003, 21:177-186.
69. Zelzer E., et al. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech. Dev. 2001, 106:97-106.